ReviewFrontiers in cell and developmental biology2026
Ubiquitin-proteasome system regulation of bone remodeling in postmenopausal osteoporosis.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postmenopausal osteoporosis (PMOP) is associated with declining estrogen levels, and this hormonal deficiency alters the physiological balance between bone formation and resorption. Substantial evidence indicates that protein homeostasis disorders play a significant role in the pathological process of PMOP. As the core system regulating protein homeostasis, the ubiquitin-proteasome system exerts crucial regulatory effects on bone metabolism under estrogen-deficient conditions. Abnormal activity of these ubiquitin-associated enzymes often leads to excessive degradation or abnormal accumulation of key regulatory proteins in bone metabolism, thereby exacerbating bone loss in PMOP. This review summarizes recent studies, focusing on how ubiquitin E3 ligases and deubiquitinating enzymes influence the function of osteoblasts and osteoclasts in PMOP. By synthesizing evidence from postmenopausal clinical samples and ovariectomized animal models, we further elucidate the specific roles of ubiquitin-related pathways in this disease. A deeper understanding of the mechanisms underlying UPS dysregulation in postmenopausal women holds promise for identifying novel molecular targets for future therapeutic strategies in PMOP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.